COLLEGIUM PHARMACEUTICAL INC (COLL)
Health Care · Specialty pain management and ADHD pharmaceuticals · NASDAQ
A specialty pharma company building a diversified pain and ADHD portfolio through branded products and acquisitions, though facing material generic headwinds on its opioid franchise.
What COLLEGIUM PHARMACEUTICAL INC does
Collegium Pharmaceutical is a diversified biopharmaceutical company that develops, licenses, and commercializes branded prescription medicines for ADHD and moderate to severe pain management. The company's portfolio includes Jornay PM (evening-dosed ADHD stimulant), Belbuca (buprenorphine-based pain treatment), Xtampza ER (abuse-deterrent oxycodone), the Nucynta products (tapentadol formulations for pain), and Symproic (opioid-induced constipation treatment), all marketed in the United States. The company builds its pipeline through acquisitions and partnerships to expand its neuropsychiatry and pain management franchises.
Themes: ["ADHD treatment / CNS stimulants","Chronic pain management / opioids","Abuse-deterrent opioid formulations","Opioid-induced constipation","Specialty pharmaceuticals"]
Fundamentals
- Price$35.81 as of 2026-07-09 close
- Market cap$1.1B as of 2026-07-10
- 1-year return+10.7% as of 2026-07-09 close
- P/E15.14 as of 2026-07-10
- Net margin+9.4% as of 2026-07-10
- Gross margin+60.7% as of 2026-07-10
- ROE+26.7% as of 2026-07-10
- Debt / equity2.57 as of 2026-07-10
- Revenue growth (YoY)+19.9% as of 2026-07-10
- Revenue CAGR (3y)+18.9% SEC XBRL
- Beta0.77 as of 2026-07-10
Key risks (from latest filing)
["Generic competition and loss of exclusivity: Third-party generic Nucynta IR launched January 2026; authorized generic versions of Nucynta IR (February 2026) and Nucynta ER (March 2026) launched by Hikma, significantly reducing revenues from these legacy products which are core to the portfolio.","Opioid regulatory and market scrutiny: All pain management products face ongoing regulatory pressure, prescriber hesitancy, and reimbursement challenges due to opioid crisis concerns; potential further restrictions could impair commercialization and pricing.","Acquisition integration and large cash outlays: Pending $650 million Azstarys acquisition plus prior acquisitions (Ironshore, BDSI) create execution risk, integration costs, and balance-sheet pressure that could constrain financial flexibility and profitability."]
Competitors & peers
- Purdue Pharma (oxycodone/opioid pain management)
- Janssen Pharmaceuticals / Johnson & Johnson (pain opioids)
- Endo Pharmaceuticals (pain management)
- Noven Pharmaceuticals (pain/transdermal delivery)
- Shionogi (pain/Nucynta originator)
- Naurex / Pfizer (ADHD stimulants)
- Adlon Therapeutics / Purdue (ADHD)
- Adzenys XR-ODT / Neos Therapeutics (ADHD)
Fundamentals: Finnhub, as of 2026-07-10. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-09.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date.